RxDoctor Payments Data

Thomas Simcox, MD

Gastroenterology · Annapolis, MDNPI 1124287461

Payments from drug & device makers

$2,024in general payments, 2019–2025

Across 101 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$256
  • Madrigal Pharmaceuticals$145
  • Echosens North America, Inc.$116
  • Pfizer$97
  • Biofire Diagnostics, LLC$68
  • plus $326 from 13 others

What the payments were for

  • Food & beverage$2,024100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,024 in reported general payments places this provider in the 40th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$186,711
Medicare patients
681
Services billed
1,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid13$123,779
CreonLipase/Protease/Amylase39$103,684
LinzessLinaclotide17$14,595
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates235$14,008
Mesalamine14$9,480
Ursodiol13$7,436
Pantoprazole Sodium347$5,592
Famotidine138$2,291
Rabeprazole Sodium14$2,207
Esomeprazole Magnesium36$1,827
Dicyclomine Hcl71$1,519
Omeprazole93$1,471
Sucralfate22$1,095
Budesonide DrBudesonide14$921
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl41$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$46$123,77913 claims
AbbVieCreon, Linzess$1,016$118,27856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →